Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuriBlood Medical CoROCO:6847 +2.91%74 Days Payable is 126.38 as of Dec. 2025, which is 198% above its 10-year median of 42.41. GuruFocus rates ROCO:6847 with a GF Score™ of 74/100 and a GF Value™ of NT$66.17 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, PuriBlood Medical Co ranks better than 70% on this metric.
The historical rank and industry rank for PuriBlood Medical Co's Days Payable or its related term are showing as below:
ROCO:6847'
s Days Payable Range Over the Past 10 Years
Min: 11.57 Med: 42.41 Max: 141.28
Current: 125.32
During the past 8 years, PuriBlood Medical Co's highest Days Payable was 141.28. The lowest was 11.57. And the median was 42.41.
ROCO:6847's Days Payable is ranked better than 70% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs ROCO:6847: 125.32
PuriBlood Medical Co's Days Payable
increased
from Dec. 2024 (64.69) to Dec. 2025 (126.38).
It may suggest that PuriBlood Medical Codelayed paying its suppliers.
PuriBlood Medical Co Days Payable Related Terms
PuriBlood Medical Co Days Payable Historical Data
* Premium members only.
The historical data trend for PuriBlood Medical Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6847 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, PuriBlood Medical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuriBlood Medical Co Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PuriBlood Medical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where PuriBlood Medical Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PuriBlood Medical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuriBlood Medical Co (ROCO:6847) has a Days Payable of 126.38 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PuriBlood Medical Co and its competitors. This is 198% above median its historical median of 42.41. Over the past decade, PuriBlood Medical Co's Days Payable has ranged from 11.57 to 141.28. According to the industry distribution chart, PuriBlood Medical Co ranks #57 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 30%.
Is PuriBlood Medical Co's Days Payable too high?
PuriBlood Medical Co's current Days Payable of 126.38 is 198% above median its 10-year median of 42.41. Over the past 10 years, this metric has ranged from a low of 11.57 to a high of 141.28. The Medical Diagnostics & Research industry median Days Payable is 64.64. PuriBlood Medical Co's value of 126.38 is 95.5% above this industry median. Based on the distribution chart, PuriBlood Medical Co ranks #57 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, PuriBlood Medical Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PuriBlood Medical Co ranks #57 out of 190 companies for Days Payable. This puts PuriBlood Medical Co in the upper half of its industry. The industry median Days Payable is 64.64. PuriBlood Medical Co's value of 126.38 is 95.5% above this benchmark. Historically, PuriBlood Medical Co's own Days Payable has ranged from 11.57 to 141.28 over the past decade. While the company's 10-year median is 42.41 vs. the industry median of 64.64, PuriBlood Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuriBlood Medical Co's current Days Payable of 126.38 is 95.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PuriBlood Medical Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuriBlood Medical Co's current Days Payable is 126.38, which is 198% above median its own 10-year median of 42.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$66.17, compared to a current price of NT$77.70 — trading 17.4% above its estimated fair value. The current Days Payable is 126.38, which is 198% above median its 10-year median of 42.41 and 95.5% above the Medical Diagnostics & Research industry median of 64.64. PuriBlood Medical Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current Days Payable is 126.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?
Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued.
The current stock price of NT$77.70 is trading 17.4% above its estimated GF Value™ of NT$66.17.
GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.
Key valuation signals for ROCO:6847:
Days Payable: 126.38 (198% above median its 10-year median of 42.41)
GF Value™: NT$66.17 vs. price of NT$77.70 (17.4% above fair value)
Industry Position: 95.5% above the Medical Diagnostics & Research median (#57 of 190)
No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
74GF Score
Get the complete analysis for ROCO:6847
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6847 has been successfully added to your 
